- Home
- TRX vs SGHT Comparison
TRX vs SGHT Comparison
Compare TRX & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRX
- SGHT
- Stock Information
- Founded
- TRX 1990
- SGHT 2011
- Country
- TRX Canada
- SGHT United States
- Employees
- TRX N/A
- SGHT N/A
- Industry
- TRX
- SGHT Medical Specialities
- Sector
- TRX
- SGHT Health Care
- Exchange
- TRX Nasdaq
- SGHT Nasdaq
- Market Cap
- TRX 228.9M
- SGHT 193.2M
- IPO Year
- TRX N/A
- SGHT 2021
- Fundamental
- Price
- TRX $0.62
- SGHT $7.23
- Analyst Decision
- TRX Strong Buy
- SGHT Buy
- Analyst Count
- TRX 2
- SGHT 8
- Target Price
- TRX $1.15
- SGHT $4.93
- AVG Volume (30 Days)
- TRX 1.2M
- SGHT 213.3K
- Earning Date
- TRX 11-28-2025
- SGHT 11-06-2025
- Dividend Yield
- TRX N/A
- SGHT N/A
- EPS Growth
- TRX N/A
- SGHT N/A
- EPS
- TRX N/A
- SGHT N/A
- Revenue
- TRX $47,731,000.00
- SGHT $76,052,000.00
- Revenue This Year
- TRX $33.23
- SGHT N/A
- Revenue Next Year
- TRX $34.65
- SGHT $12.04
- P/E Ratio
- TRX $602.23
- SGHT N/A
- Revenue Growth
- TRX 29.98
- SGHT N/A
- 52 Week Low
- TRX $0.27
- SGHT $2.03
- 52 Week High
- TRX $0.85
- SGHT $8.06
- Technical
- Relative Strength Index (RSI)
- TRX 47.12
- SGHT 69.14
- Support Level
- TRX $0.61
- SGHT $6.74
- Resistance Level
- TRX $0.67
- SGHT $7.24
- Average True Range (ATR)
- TRX 0.05
- SGHT 0.51
- MACD
- TRX -0.00
- SGHT 0.03
- Stochastic Oscillator
- TRX 46.90
- SGHT 75.00
About TRX TRX Gold Corporation
TRX Gold Corp is a mineral resource company. It is engaged in the acquisition of interests and the exploration of natural resource properties. Its mineral properties are located in the United Republic of Tanzania. The company's main area of interest has been in the exploration and development of gold properties. It is focused on the Buckreef Gold Project which comprises five prospects, namely Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.